GRI Bio, Inc. Common Stock (GRI) Stock Price
GRIStock
$1.96−95.43%52W
Market Cap$4.28M
P/E—
PEG Ratio—
Div yield—
Beta-1.21
GRI Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-39.93%
Price vs S&P 500 (4W)22.12%
VGM Score15.72
GRI Earnings Surprise History
Q2 25-36.68est. -36.68
Q3 25-35.84est. -31.08
Q4 25-116.61est. -29.26
Q1 26-1.61est. -3.74
Q2 26-0.91est. -1.20
GRI Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GRIGRI Bio, Inc. Common Stock | — | — | F | $1.96 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About GRI Bio, Inc. Common Stock
GRI Bio is a clinical-stage biotech company developing immunomodulatory therapies for inflammatory, fibrotic, and autoimmune disorders. Its lead program, GRI-0621, is a RAR-beta/gamma dual agonist that modulates immune T cell responses, with an oral tazarotene formulation also in development. The company's pipeline includes GRI-0803, a Type 2 NKT cell agonist designed to treat autoimmune conditions.